BDX

SIX:BDX

BD

Add to Watchlist
  • Stock

169.54

−18.13%

−15.78

USD last updated 28/07 01:48:46

Last Close

185.32

25/07 22:30

Market Cap

64.70B

Beta: -

Volume Today

12.49M

Avg: -

PE Ratio

42.47

PFCF: 53.11

Dividend Yield

0.37%

Payout:66.54%

BD, a healthcare company, announced the initiation of its first pharma-sponsored clinical trial utilizing its wearable injector technology for biologics.

healthcarepackaging.com

The global drug delivery infusion system market is projected to reach US$22.62 billion by 2033, growing at a 6.8% CAGR. Key drivers include advancements in MRI-compatible pumps, precision therapy solutions, and expanded use in oncology, homecare, and telehealth. Major players like Medtronic, Eitan Medical, and ICU Medical have received FDA clearances for innovative devices, while regions like Japan and the U.S. lead in adoption due to aging populations and healthcare infrastructure.

openpr.com

The global cell analyzer market is projected to grow at a 8% CAGR from 2025 to 2030, driven by advancements in cell analysis technologies, rising demand for single-cell analysis, and automation in research and clinical applications. Key applications include drug discovery, immunology, oncology, and regenerative medicine, with major players like Becton Dickinson and Thermo Fisher Scientific leading the industry.

pharmiweb.com

Becton, Dickinson and Company (BDX) received an average 'Hold' rating from 11 brokerages, with 7 analysts rating it 'Hold' and 4 'Buy'. The average 1-year target price is $219.22. Analysts including Raymond James, Wells Fargo, and Goldman Sachs downgraded the stock. The company reported $3.35 EPS, exceeding estimates, with $5.27B revenue. Insiders sold shares, and institutional investors increased positions. The company declared a $1.04 quarterly dividend.

defenseworld.net

BD announced a trial using the BD Libertas wearable injector for subcutaneous delivery of biologics, following positive results from over 50 pre-clinical and clinical studies. The device features a transparent window, push-button activation, and color-coded status indicators, and is not subject to FDA 510(k) or EU CE mark certification, enabling faster commercialization. BD is validating fill-finish processes with contract manufacturers to support pharmaceutical collaborators.

finance.yahoo.com

    Description

    Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral ca...Show More

    Earnings

    Earnings per Share (Estimate*)

    -11232018-03-312019-03-302020-03-312021-03-312022-03-30

    Revenue (Estimate*)

    1B2B3B4B5B2018-03-312019-03-302020-03-312021-03-312022-03-30

    *Estimate based on analyst consensus